

SINGAPORE O&G LTD. (Company Registration No. 201100687M)

FOR IMMEDIATE RELEASE

Singapore O&G Achieves Steady Results for 1Q 2017

- Announces Group's first quarterly results since IPO
- 1Q 2017 Group Revenue of S\$7.0 million, up 6.1% as compared to 1Q 2016
- Net Profit after tax for the period up marginally by 2.8% to approximately S\$2.0 million

Singapore, 12 May 2017 – Singapore O&G Ltd. ("**SOG**" or collectively with its subsidiaries, the "**Group**"), a SGX Catalist listed company specialising in women's healthcare, announced today its unaudited financial results for the first quarter ended 31 March 2017 ("**1Q 2017**"). The Group's net profit after tax attributable to shareholders increased by S\$0.05 million or 2.8%, and revenue increased by S\$0.4 million or 6.1%, over the same period last year ("**1Q 2016**"). Net profit after tax margin decreased by 1.0% from 29.6% in 1Q 2016 to 28.6% in 1Q 2017.

Seasonally the first quarter is the slowest quarter of the year for the Group. Despite this, the Group was still able to garner a small increase in total revenue and net profit after tax. The core segment Obstetrics and Gynaecology ("O&G") continues to deliver a healthy number of babies in 1Q 2017, totalling 404 babies, an increase of 9.8% as compared to 1Q 2016. Combined revenues from the O&G and Cancer-related segments continue to register growth with the Dermatology segment showing consolidation.

Dr. Ng Koon Keng, CEO of SOG said "From our close observation of the Zika Virus outbreak in Singapore, it appears that the localised community spread had some effect on couple's decision to conceive in 2016 as seen in a slight dip in the total number of live births from 9,812 babies in 1Q of 2016 to 9,762 babies for the same period in 2017. However, we anticipate the birth numbers to pick up towards the end of the year as the fears related to the Zika Virus appears to have abated.

Singapore O&G Ltd.

Against this backdrop, SOG has increased its efforts to engage our patients with our range of services through various marketing initiatives like our Patient Retention Program. We have also started to promote skin care products from our SOG Dermatology through our O&G clinics.

On 5 April 2017, we announced the incorporation of SOG Children (Paediatrics) Pte. Ltd. and our paediatric services should commence in July 2017. We are confident that the addition of this pillar will drive greater growth to our business and at the same time allow us to cater to the healthcare needs of a group of new and young patients."

– END –

ABOUT SINGAPORE O&G LTD. ("SOG" or collectively with its subsidiaries, the "Group")

SOG is a leading group of Specialist Medical Practitioners dedicated towards women's health and wellness with a long and established track record in the Obstetrics and Gynaecology ("O&G") field.

SOG's goal is to provide women comprehensive life-long health and wellness. Currently, our specialties are: pregnancy care and delivery; the female reproductive system; gynaecological and breast cancer; skin and aesthetic treatments; and other ancillary medical services.

As at 31 March 2017, the Group has a total of ten Specialist Medical Practitioners:

- Six O&G Specialists;
- Three cancer specialists: One Obstetrician/GynaeOncologist and two Breast and General Surgeons; and
- One Dermatologist.

The Group is led by its Chairman, Dr. Heng Tung Lan, its CEO, Dr. Ng Koon Keng and its Executive Directors, Dr. Lee Keen Whye and Dr. Beh Suan Tiong. In particular, both Dr. Heng Tung Lan and Dr. Lee Keen Whye have more than 20 years' experience in the O&G field. Additionally, Dr. Ng Koon Keng has business development, management, marketing and publishing experience and spearheads the marketing and business development activities of the Group.

For more information, please visit SOG's website at <u>www.sog.com.sg</u>.

For media and analyst queries, please contact:

Investor Relations Singapore O&G Ltd. Tel: +65 6440 4123 Fax: +65 6440 8240 Email: ir@sog.com.sg

The contact person for the Sponsor is Mr. Tang Yeng Yuen, Vice-President, Head of Corporate Finance, at 16 Raffles Quay, #40-01A Hong Leong Building, Singapore 048581. Telephone number: (65) 6415 9886.

This Press Release has been prepared by the Company and its content has been reviewed by the Company's sponsor, Hong Leong Finance Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this Press Release. This Press Release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Press Release including the correctness of any of the statements or opinions made or reports contained in this Press Release.